Researchers target metastases
Italian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2209 entries already.
Entries by Thomas Gabrielczyk
Vifor Pharma in €70m pruritus drug deal
Vifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).
Fighting AMR: turning the p(h)age
The rapid development of antibiotic resistance has become a major public health issue that could soon kill 10 million people annually. One promising alternative to ineffective antibiotics has been around for almost a century – bacteriophages. The microbe-killing viruses are used in medicine in Georgia, Poland and Russia, but have been neglected by western doctors. Now pressure is mounting on global health authorities to put the option back on the table.
Evotec signs US$65m deal with Celgene
Evotec AG and Celgene Corporation have entered into a strategic drug discovery and development partnership to identify new therapeutics in oncology.
Biomaterials growth and crash side by side
Bioeconomy industry experts gave a mixed outlook for biomaterials in mid-May in Cologne where about 200 stakeholder joined the 11th International Conference on Bio-based Materials.
Cell type switch helps colon cancer evade treatment
Researchers at LMU Munich have unraveled a new strategy of colon cancers to evade targeted therapies.
Kite expands cell therapy manufacturing in Europe
CAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, will be operational by 2020.
bluebird bio expands US$1bn deal with MediGene
CAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement.
AZ COPD drug fails in Phase III study
British drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
3-D printed device delivers drugs in humans
A research team headed by Jean-Christophe Leroux from ETH Zurüch has created the first-ever 3-D printed mouth guard that could deliver drugs to the wearer and is highly customizable, in terms of drug release and design.